Menveo

Meningococcal Group Y Oligosaccharide Conjugated To Corynebacterium diphtheriae CRM197 Protein, the active ingredient in Menveo, is a vaccine presented as an injectable solution for intramuscular use. It is used to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, W‑135 and Y in individuals at risk.

GNH USA supplies Menveo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Menveo is a conjugate vaccine that targets the capsular polysaccharides of Neisseria meningitidis, providing protection against invasive meningococcal disease.

Invasive meningococcal disease (serogroups A, C, W‑135, Y): Provides active immunity to prevent infection. Travel to endemic regions: Reduces risk of acquiring meningococcal disease during travel. Adolescents and young adults: Offers protection for high‑risk age groups.

Common side effects are generally mild and resolve without medical intervention.

Common Side Effects: - Injection site pain: mild to moderate soreness at the injection site. - Redness or swelling: localized erythema or edema. - Fever: transient low‑grade temperature elevation. - Headache: mild headache occurring within 24 hours. - Fatigue: temporary feeling of tiredness. - Muscle aches: mild myalgia after vaccination.

Serious or Rare Side Effects: - Severe allergic reaction (anaphylaxis): rapid onset of hives, airway swelling, hypotension. - Guillain‑Barré syndrome: rare neurological disorder causing muscle weakness. - Seizures: infrequent occurrence of convulsive episodes. - High fever (>40 °C): persistent high temperature requiring medical attention. - Serum sickness‑like reaction: rash, joint pain, fever. - Neurological complications: rare cases of meningitis or encephalitis.

Before administering Menveo, consider the following precautions to ensure safe use.

Allergy assessment: avoid use in individuals with known hypersensitivity to any vaccine component. Medical history review: defer vaccination in persons with severe immunodeficiency. Pregnancy consideration: discuss risks and benefits with healthcare provider. Concurrent illness: postpone vaccination if acute moderate or severe illness is present. Post‑vaccination observation: monitor for at least 15 minutes for immediate reactions. Store at 2‑8 °C: keep refrigerated, protect from light, do not freeze or shake.

Menveo may interact with certain therapies or vaccines; review patient medication history.

Major Interactions (Avoid): - Live bacterial vaccines: concurrent administration may reduce immune response; separate by at least 4 weeks. - Immunoglobulin therapy: may interfere with vaccine efficacy; postpone vaccination for 3 months after therapy. - Blood products containing anti‑meningococcal antibodies: avoid within 6 weeks.

Moderate Interactions (Monitor Closely): - Antipyretics (acetaminophen, ibuprofen): may mask fever, monitor for underlying reaction. - Immunosuppressive drugs (e.g., corticosteroids): may diminish antibody response; assess immunity post‑vaccination. - Other vaccines administered simultaneously: monitor for additive local reactions.